Advertisement

Cavernous Sinus Thrombosis - Biotech, Pharma and Life Science Channel

23:07 EDT 19th June 2013 | BioPortfolio

PubMed Articles [ 3094 Associated PubMed Articles listed on BioPortfolio]

Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.

Zoledronic acid (ZA) is one of the important bisphosphonates which is widely used in bone metastatic cancer and osteoporotic patients. In a few studies, it has been reported that treatment with bispho...

Identification of a Novel Mode of Complement Activation on Stimulated Platelets Mediated by Properdin and C3(H2O).

Elevated numbers of activated platelets circulate in patients with chronic inflammatory diseases, including atherosclerosis and coronary disease. Activated platelets can activate the complement system...

Malignant meningitis presenting as pseudotumor cerebri.

Malignant leptomeningitis can present as the clinical syndrome of pseudotumor cerebri due to infiltration of arachnoid villi in the superior sagittal sinus. We show that malignant pachymeningitis can...

Risk of recurrence of unusual site venous thromboembolism.

The term unusual site venous thrombosis defines uncommon clinical manifestations of venous thromboembolism occurring in sites different from the lower limbs or the lungs, with peculiar pathophysiologi...

Primary antiphospholipid syndrome: newly developed leg ulcer and history of stroke.

Antiphospholipid syndrome features not only deep vessel thrombosis but also may have cutaneous manifestations such as Raynaud phenomenon, acral necrosis, livedo reticularis, subcutaneous nodules, and...

Dual-energy subtraction radiography improves laryngeal delineation in patients with moderate to severe cervical spondylosis.

PURPOSE: To investigate the feasibility of dual-energy subtraction (DES) in patients with moderate-severe cervical spondylosis for improving delineation of the larynx on flat panel detector (FPD) radi...

The CCM3-GCKIII partnership.

Specific mutations in the CCM3 gene predispose to the development of cerebral cavernous malformations, a special type of vascular lesions. This calls for an elucidation of the precise nature of the CC...

Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation.

Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes.

Genome-wide linkage scan in affected sibling pairs identifies novel susceptibility region for venous thromboembolism: Genetics In Familial Thrombosis (GIFT) study.

BACKGROUND: Venous thromboembolism (VTE) is a multicausal disorder involving environmental and genetic risk factors. In many thrombophilic families the clustering of thrombotic events cannot be explai...

News Articles [ 575 Associated News Articles listed on BioPortfolio]

GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen

Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arix...

AngioScore Announces Completion of Enrollment in Drug-Coated AngioSculpt® Scoring Balloon Catheter First-in-Human Study

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the completion of enrollment in the Drug-Coated An...

Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site

UK pharma giant GlaxoSmithKline (LSE: GSK) said yesterday (June 18) that it has received an offer for its thrombosis brands and Notre-Dame de Bondeville (NDB) site from Aspen Global and Aspen Pharmaca...

Aspen proposes to acquire GSK's thrombosis brands and NDB site

Research-based pharmaceutical and healthcare company GlaxoSmithKline (GSK) has received a proposal from Aspen Global and Aspen Pharmacare Holdings for its thrombosis brands and Notre-Dame de Bondevill...

Aspen Bids To Buy Thrombosis Drugs, Production Plant From GSK

Aspen Pharmacare has made a bid to acquire GlaxoSmithKline's line of thrombosis drugs as well as their production plant that could add more than $400 million a year to revenues.

Scientists Link Genetic Contributor To Heart Disease Risk

Lee Rannals for redOrbit.com – Your Universe Online Researchers from the University of Leicester have identified a potential genetic contributor that leads to an increased risk of heart disease in...

GSK receives offer for thrombosis brands

GSK has received an offer from South African pharma company, Aspen, and it's wholly owned subsidiary, Aspen Global Incorporated, for its thrombosis brands and Notre-Dame de Bondeville (NDB) manufactur...

GlaxoSmithKline Gets Offer For Its Thrombosis Brands From Aspen Pharmacare

LONDON (dpa-AFX) - U.K.-based drug maker GlaxoSmithKline plc (GSK, GSK.L) said Tuesday that it has received an offer for its thrombosis brands and a related production site in France from South Af...

GSK negotiating $1 billion sale of thrombosis drugs to Aspen

LONDON (Reuters) - GlaxoSmithKline is discussing the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could be worth...

UPDATE 1-GSK negotiating $1 bln sale of thrombosis drugs to Aspen

* Aspen offers to buy Arixtra and Fraxiparine, plus factory

Events [0 Results]

None

Companies [ 9 Associated Companies listed on BioPortfolio]

Merck and Cardiome Pharma Corp.

In April 2009, Cardiome and Merck announced a collaboration and license agreement for the development and commercialization of vernakalant. The agreement provides Merck, Sharp and...

Osprey Medical, Inc.

Osprey Medical is a privately held company located in Eden Prairie, Minnesota. The Company is dedicated to the treatment and prevention of ailments originating from the inter-rela...

SinuSys Corp.

Chronic sinusitis affects more than 31 million people in the United States. It is more prevalent than heart disease and asthma, and has a greater impact on patients’ quality...

Ariste Medical, Inc.

Ariste Medical, Inc. is a privately held biotechnology company developing novel, first-in-class, drug-eluting devices to reduce infection, restenosis, and thrombosis. Located in t...

EKOS Corporation

EKOS Corporation pioneered the development and clinical application of ultrasonic accelerated drug delivery in medicine, introducing its first system for the treatment of vascular...

MaxPoint Interactive

Using its unique Digital Zip technology, MaxPoint Interactive analyzes billions of data points consumed by neighborhoods across the U.S. such as: offline point of sale data...

BioInvent International AB and ThromboGenics NV

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based

Canyon Pharmaceuticals

Canyon PharmaceuticalsTM is a privately-held specialty biopharmaceuticals company focused on delivering innovative therapeutic solutions that target important cellular pathways in...

Vicks

As a trusted family brand for more than 100 years and one of the most recognized around the world, Vicks has helped generation after generation feel relief from cough, cold, flu and sinus symptoms. Ny...

Clinical Trials [ 391 Associated Clinical Trials listed on BioPortfolio]

Relative Bioavailability of Oral Suspension of Rivaroxaban Compared to Standard Tablet

Rivaroxaban is a substance developed for use in the treatment of blood coagulation disorders. Thrombosis (blood clots) can occur as a result of excessive coagulation activity in the blood...

Belgian Real Life Non-interventional Study (NIS) in Patients Treated With Xarelto Following an Acute Deep Vein Thrombosis (DVT)

The objective of this NIS is to assess in a real-life setting, usage patterns and associated outcomes in the management (healthcare resource utilisation and associated costs) of patients w...

The Catheter Study: Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis

The purpose of this study is to obtain an estimate of catheter survival in the setting of upper extremity deep vein thrombosis (UEDVT) in patients treated with dalteparin and warfarin....

Use of Low Molecular Weight Heparin (Tinzaparin) to Treat Blood Clots in Patients With Kidney Failure

Blood clots in the leg veins, known as deep vein thrombosis, are important because they may travel to the lung (known as pulmonary embolism) and cause death. Blood clots are treated with...

PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)

The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein...

Vein-Coronary Atherosclerosis And Rosiglitazone After Bypass Surgery: The VICTORY Trial

HYPOTHESES - Rosiglitazone in diabetic patients with previous coronary bypass surgery may prevent or slow the progression of atherosclerosis in SVGs and native coronary arteries....

Failed Retrieval of Inferior Vena Cava (IVC) Filters: Long-Term Outcomes

The inferior vena cava (IVC) is a large vein that enters the bottom part of the heart. Venous blood from the lower portion of the body drains into the IVC. The IVC then returns blood back...

Characterizing and Diagnosis’s of the Charcot Foot (Charcot Osteoarthropathy) in Diabetic Patients

The condition Charcot foot has been known in more than 130 years, and yet there still remains a large effort to find the cause, diagnostic and medical treatment of the condition. Charcot...

Feasibility Study of Photopheresis Post Angioplasty

The primary objective of the study is to evaluate the difference in 6-month restenosis rates in coronary artery lesions treated by photopheresis in addition to angioplasty with stent place...

Oral Vitamin K for Warfarin Associated Coagulopathy

Excessive prolongation of the international normalized ratio (INR) occurs frequently in patients taking warfarin; in fact, about one in six INR values is above the desired range. Excessive...

Medical and Biotech [MESH] Definitions

Intermittent Pneumatic Compression Devices

Instruments that generate intermittent forces, uniformed or graduated, to facilitate the emptying of VEINS. These devices are used to reduce limb EDEMA and prevent venous THROMBOEMBOLISM, such as deep vein thrombosis in the legs.

Fibrin Modulating Agents

Agents that affect the function of FIBRIN in BLOOD COAGULATION. They used as COAGULANTS for HEMORRHAGE or ANTICOAGULANTS for THROMBOSIS.

Apoprotein(a)

A large and highly glycosylated protein constituent of LIPOPROTEIN (A). It has very little affinity for lipids but forms disulfide-linkage to APOLIPOPROTEIN B-100. Apoprotein(a) has SERINE PROTEINASE activity and can be of varying sizes from 400- to 800-kDa. It is homologous to PLASMINOGEN and is known to modulate THROMBOSIS and FIBRINOLYSIS.

Stockings, Compression

Tight coverings for the foot and leg that are worn to aid circulation in the legs and prevent the formation of EDEMA and DEEP VEIN THROMBOSIS. PNEUMATIC COMPRESSION STOCKINGS serve a similar purpose especially for bedridden patients and following surgery.

Superior Sagittal Sinus

The long large endothelium-lined venous channel on the top outer surface of the brain. It receives blood from a vein in the nasal cavity, runs backwards, and gradually increases in size as blood drains from veins of the brain and the DURA MATER. Near the lower back of the CRANIUM, the superior sagittal sinus deviates to one side (usually the right) and continues on as one of the TRANSVERSE SINUSES.

Search BioPortfolio:
Advertisement
review and buy Cavernous Sinus Thrombosis market research data and corporate reports here

Channels Quicklinks

Advertisement